Ian Adcock is Professor of Respiratory Cell & Molecular Biology and Head of the Molecular Cell Biology Group at the National Heart & Lung Institute, Imperial College London. He also holds an honorary research position at the Royal Brompton Hospital enabling him to translate the basic research activities into the clinical environment.
Professor Adcock obtained a degree in Biochemistry & Physiology from the University of London and later a PhD in Pharmacology from St Thomas”s Hospital London on the role of nuclear receptors on sexual dimorphic patterns in the rat. He performed postdoctoral training at the MRC Brain Metabolism Unit with Professors Tony Harmar and George Fink and in the Protein Science Laboratory at St Georges’ Hospital with Professor Brian Austen. He joined Professor Peter Barnes at the National Heart & Lung Institute in 1990 to undertake research on the effects of corticosteroids on inflammatory mediators in asthma and COPD. This remains his major research area along with a long-term interest in the mechanisms underlying relative steroid insensitivity in severe asthma and COPD.
Professor Adcock is an internationally recognized scientist in the field of airways disease and inflammation. He has authored and co-authored over 230 scientific articles and has served on the editorial boards of several journals. He has worked as an expert member on national grant-awarding organizations including UK MRC, US NIH, Australian NHMRC and Canadian MRC. He has served on the ERS Council and is currently a member of the ERS Scientific Program Committee and Head of the ERS Airway Pharmacology and Treatment Section.
Professor Adcock is a principal investigator in the Medical Research Council/Asthma UK Centre in Allergic Mechanisms of Asthma and in the Wellcome Trust Respiratory Infections Centre. His research is currently funded by grants from the Medical Research Council, Wellcome Trust, BHF, Royal Society, EU, BBSRC, EPSRC and Industrial collaborators. He is also a principal investigator in the European consortium UBIOPRED on mechanisms of severe asthma that is funded through the Innovative Medicine Initiative of the European Union and EFPIA.
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!